---
meta-og:type: article
---

### [◀返回](./home.md)

# 分析能力抑制

**分析能力抑制** (Analysis depression) 被定义为一个人处理信息[\[1\]](#cite_note-KnowlesDavid2010-1)[\[2\]](#cite_note-TakeuchiSuzuki2013-2)[\[3\]](#cite_note-FriedWatkinson2005-3) 以及对概念、想法和场景进行逻辑或创造性分析的能力出现了明显的下降哦。[\[4\]](#cite_note-KawaiYamakawa2006-4) 这种效应会导致咱们在思考或理解基本概念时遇到很大的困难呢，甚至会暂时阻碍正常的认知功能运作嘛。

分析能力抑制经常伴随着其他效应一起出现，比如[镇静](/药效/镇静.md "Sedation")、[思维减速](/药效/思维减速.md "Thought deceleration")和[情绪抑制](/药效/情绪抑制.md "Emotion suppression")。这种现象最常见于服用了[严重](/文档/药物剂量分类.md#heavy "Dosage") [剂量](/文档/给药剂量.md "Dosage")的[抗精神病药](/文档/抗精神病药.md "Antipsychotic")的时候，[\[1\]](#cite_note-KnowlesDavid2010-1)[\[2\]](#cite_note-TakeuchiSuzuki2013-2)[\[4\]](#cite_note-KawaiYamakawa2006-4) 同时也和长期使用这类药物有关，[\[5\]](#cite_note-HusaMoilanen2017-5) 比如[喹硫平](/药物/喹硫平.md "Quetiapine")、[氟哌啶醇](/药物/氟哌啶醇.md "Haloperidol")和[利培酮](/药物/利培酮.md "Risperidone")。不过呢，在服用了[严重](/文档/药物剂量分类.md#heavy "Dosage")剂量的[解离剂](/文档/药物分类/解离剂.md "Dissociative")、[大麻类](/文档/药物分类/大麻类.md "Cannabinoid")[\[3\]](#cite_note-FriedWatkinson2005-3) 和 [GABA类](/文档/GABA.md "GABAergic") [抑制剂](/文档/药物分类/抑制剂.md "Depressant")[\[6\]](#cite_note-ParaherakisCharney2009-6) 时，这种效应也可能以一种不太持续的形式出现哦。

## 目录

* [1 精神活性物质](#Psychoactive_substances)
* [2 体验报告](#Experience_reports)
* [3 另见](#See_also)
* [4 外部链接](#External_links)
* [5 参考文献](#References)

<!-- 请勿删除或修改，这是一个标记，待识别并填坑（药效索引） -->

### 体验报告

在我们的[体验报告索引](/文档/体验报告索引.md "Experience index")中，描述了这种效应的轶事报告包括：

* [体验报告: 22mg 2C\-B (口服) / 100ug 1P\-LSD (舌下含服) \- 我第一次独自旅程 (连续两天)](/报告/psychounautwiki/Experience:_22mg_2C-B_(oral)_/_100ug_1P-LSD_(sublingual)_-_My_first_time_tripping_alone_(2_days_in_a_row) "Experience: 22mg 2C-B (oral) / 100ug 1P-LSD (sublingual) - My first time tripping alone (2 days in a row)")
* [体验报告: 25mg 2C\-E (口服) \- 一次令人震撼的经历](/报告/psychounautwiki/Experience:_25mg_2C-E_(oral)_-_A_mindblowing_experience "Experience: 25mg 2C-E (oral) - A mindblowing experience")
* [体验报告: 1贴 LSD (未知剂量) \- 选择亚洲](/报告/psychounautwiki/Experience:1_hit_LSD_(unknown_dosage)_-_Choose_Asia "Experience:1 hit LSD (unknown dosage) - Choose Asia")
* [体验报告: 25mg 2C\-B \- 在家狂欢](/报告/psychounautwiki/Experience:25mg_2C-B_-_Hard_raving_at_home "Experience:25mg 2C-B - Hard raving at home")
* [体验报告: 2mg 依替唑仑 \- 龙潭虎穴](/报告/psychounautwiki/Experience:2mg_Etizolam_-_Here_be_dragons "Experience:2mg Etizolam - Here be dragons")
* [体验报告: 3mg 依替唑仑 \- 一种用来度过下降期的药](/报告/psychounautwiki/Experience:3mg_Etizolam_-_A_Comedown_Drug "Experience:3mg Etizolam - A Comedown Drug")
* [体验报告: 50mg \- 二苯啶之旅](/报告/psychounautwiki/Experience:50mg_-_Diphenidine_ride "Experience:50mg - Diphenidine ride")
* [体验报告: 右美沙芬和大麻: 100mg \- 意想不到的强烈旅程](/报告/psychounautwiki/Experience:DXM_and_Cannabis:_100mg_-_Unexpected_Strong_Trip "Experience:DXM and Cannabis: 100mg - Unexpected Strong Trip")
* [体验报告: 未知剂量的 DOC (鼻吸) \- 药物过量和可怕的自我死亡](/报告/psychounautwiki/Experience:Unknown_Dose_DOC_(Insufflated)_-_Overdosing_and_Terifying_Ego_Death "Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death")
* [体验报告: 未知剂量 \- 超市里的错位和骑行](/报告/psychounautwiki/Experience:Unknown_dose_-_Supermarket_dislocation_and_biking "Experience:Unknown dose - Supermarket dislocation and biking")
* [体验报告: \~150mg MDA(口服) \- 一个身份认同错误的案例](/报告/psychounautwiki/Experience:~150mg_MDA(oral)_-_a_case_of_mistaken_identity "Experience:~150mg MDA(oral) - a case of mistaken identity")


### 另见

* [负责任的用药](/文档/负责任的用药索引页.md "Responsible use")
* [主观效应索引](/药效/home.md "Subjective effects index")
* [迷幻剂 \- 主观效应](/文档/药物分类/迷幻剂.md#Subjective_effects "Psychedelics")
* [解离剂 \- 主观效应](/文档/药物分类/解离剂.md#Subjective_effects "Dissociatives")
* [谵妄剂 \- 主观效应](/文档/药物分类/谵妄剂.md#Subjective_effects "Deliriants")


### 外部链接

* [精神分析 (维基百科)](https://en.wikipedia.org/wiki/Psychoanalysis)


### 参考文献

1. ↑ [1\.0](#cite_ref-KnowlesDavid2010_1-0) [1\.1](#cite_ref-KnowlesDavid2010_1-1) Knowles, Emma E.M.; David, Anthony S.; Reichenberg, Abraham (2010\). "Processing Speed Deficits in Schizophrenia: Reexamining the Evidence". *American Journal of Psychiatry*. **167** (7\): 828–835\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1176/appi.ajp.2010\.09070937](//doi.org/10.1176%2Fappi.ajp.2010.09070937). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0002\-953X](//www.worldcat.org/issn/0002-953X). 
2. ↑ [2\.0](#cite_ref-TakeuchiSuzuki2013_2-0) [2\.1](#cite_ref-TakeuchiSuzuki2013_2-1) Takeuchi, H.; Suzuki, T.; Remington, G.; Bies, R. R.; Abe, T.; Graff\-Guerrero, A.; Watanabe, K.; Mimura, M.; Uchida, H. (2013\). "Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open\-Label, Randomized, Controlled, Pilot Study". *Schizophrenia Bulletin*. **39** (5\): 993–998\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1093/schbul/sbt090](//doi.org/10.1093%2Fschbul%2Fsbt090). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0586\-7614](//www.worldcat.org/issn/0586-7614). 
3. ↑ [3\.0](#cite_ref-FriedWatkinson2005_3-0) [3\.1](#cite_ref-FriedWatkinson2005_3-1) Fried, P; Watkinson, B; Gray, R (2005\). "Neurocognitive consequences of marihuana—a comparison with pre\-drug performance". *Neurotoxicology and Teratology*. **27** (2\): 231–239\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/j.ntt.2004\.11\.003](//doi.org/10.1016%2Fj.ntt.2004.11.003). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0892\-0362](//www.worldcat.org/issn/0892-0362). 
4. ↑ [4\.0](#cite_ref-KawaiYamakawa2006_4-0) [4\.1](#cite_ref-KawaiYamakawa2006_4-1) Kawai, Nobutoshi; Yamakawa, Yuriko; Baba, Atsuomi; Nemoto, Kiyotaka; Tachikawa, Hirokazu; Hori, Takafumi; Asada, Takashi; Iidaka, Tetsuya (2006\). "High\-dose of multiple antipsychotics and cognitive function in schizophrenia: The effect of dose\-reduction". *Progress in Neuro\-Psychopharmacology and Biological Psychiatry*. **30** (6\): 1009–1014\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/j.pnpbp.2006\.03\.013](//doi.org/10.1016%2Fj.pnpbp.2006.03.013). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0278\-5846](//www.worldcat.org/issn/0278-5846). 
5. [↑](#cite_ref-HusaMoilanen2017_5-0) Husa, Anja P.; Moilanen, Jani; Murray, Graham K.; Marttila, Riikka; Haapea, Marianne; Rannikko, Irina; Barnett, Jennifer H.; Jones, Peter B.; Isohanni, Matti; Remes, Anne M.; Koponen, Hannu; Miettunen, Jouko; Jääskeläinen, Erika (2017\). "Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort". *Psychiatry Research*. **247**: 130–138\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/j.psychres.2016\.10\.085](//doi.org/10.1016%2Fj.psychres.2016.10.085). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0165\-1781](//www.worldcat.org/issn/0165-1781). 
6. [↑](#cite_ref-ParaherakisCharney2009_6-0) Paraherakis, Antonios; Charney, Dara A.; Gill, Kathryn (2009\). "NEUROPSYCHOLOGICAL FUNCTIONING IN SUBSTANCE\-DEPENDENT PATIENTS". *Substance Use \& Misuse*. **36** (3\): 257–271\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1081/JA\-100102625](//doi.org/10.1081%2FJA-100102625). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1082\-6084](//www.worldcat.org/issn/1082-6084).
